Question for written answer P-004527/2018
to the Commission
Rule 130
Alex Mayer (S&D)

Subject: The relocation of the European Medicines Agency (EMA)

The relocation of the EMA from London to Amsterdam has led to a reduction in the agency's staff and a short-term plan to scale back its activities ahead of the move.

Could the Commission please outline:

1. With regard to the suspension of the publication of clinical data to support applications for regulatory approval, and the scaling down of the development of scientific guidelines for regulatory approval applications for medicines, what assessment has the Commission carried out of a potential increase in the likely timeframe for regulatory approval applications, and a possible decrease in companies' success in reaching regulatory approval for treatments?

2. With regard to the scaling back of international collaborations, what assessment has been carried out of the effect on the harmonisation of global medicine regulations?

3. Which stakeholder meetings does the Commission consider that the EMA should but will not attend given its reduced staffing levels?